Latest News & Updates
Breaking News
16 hours ago
Simantini Singh Deo
Cellectis Achieves 100% ORR with Lasme-cel in Phase 1 BALLI-01 Trial, Advances to Pivotal Phase 2
Pharma Now Editorial Team
Roche Gains FDA Priority Review for Tecentriq sBLA in Stage III dMMR Colon Cancer
Pharma Now Editorial Team
Other trending news you may like to read
Novartis del-brax Achieves Phase I/II Primary Endpoint in FSHD, Phase III Enrolling
Novartis FORTITUDE Phase I/II data confirm del-brax target engagement in FSHD; Phase III enrolling and regulatory discussions planned.
Simantini Singh Deo
Curium Group Completes Patient Dosing in 64Cu-PSMA-I&T Phase 2 Trial for Prostate Cancer in Japan
Curium Group completes patient dosing in Japan's Phase 2 trial for 64Cu-PSMA-I&T; data analysis now underway to support regulatory submission.
Simantini Singh Deo
Cellectis Achieves 100% ORR with Lasme-cel in Phase 1 BALLI-01 Trial, Advances to Pivotal Phase 2
Cellectis reports 100% ORR for lasme-cel in BALLI-01 Phase 1, advancing to Pivotal Phase 2 with interim data expected Q4 2026.
Pharma Now Editorial Team
Roche Gains FDA Priority Review for Tecentriq sBLA in Stage III dMMR Colon Cancer
Roche's Tecentriq sBLA earns FDA Priority Review with a 9 October 2026 PDUFA date for adjuvant use in stage III dMMR colon cancer.
Pharma Now Editorial Team
